Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
NCT ID: NCT01757535
Last Updated: 2025-07-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
472 participants
INTERVENTIONAL
2013-04-24
2024-06-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is amended to include an extension phase (EP). The EP allows participants who are currently receiving oral azacitidine and who are demonstrating clinical benefit as assessed by the investigator, to continue receiving oral azacitidine after unblinding by sponsor until the participant meets the criteria for study discontinuation or until oral azacitidine becomes commercially available and reimbursed. In addition, all participants in the placebo arm and participants who had been discontinued from the treatment phase (irrespective of randomization arm) and continuing in the follow-up phase will be followed for survival in the EP.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
NCT05197426
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
NCT05413018
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
NCT02450877
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
NCT00497991
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
NCT05641259
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study is amended to include an extension phase (EP). The EP allows participants who are currently receiving oral azacitidine and who are demonstrating clinical benefit as assessed by the Investigator, to continue receiving oral azacitidine after unblinding by sponsor until they meet the criteria for study discontinuation or until oral azacitidine becomes commercially available and reimbursed. In addition, all participants in the placebo arm and participants who had been discontinued from the treatment phase (irrespective of randomization arm) and continuing in the follow-up phase will be followed for survival in the EP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Azacitidine
300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
Oral Azacitidine
300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
Placebo
Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Placebo
Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Azacitidine
300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
Placebo
Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Newly diagnosed, histologically confirmed de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or CMML (Chronic myelomonocytic leukemia)
3. First complete remission (CR)/ complete remission with incomplete blood count recovery (CRi) with induction therapy with intensive chemotherapy with or without consolidation therapy within 4 months (+/- 7 days of achieving CR or CRi)
4. Eastern Cooperative Oncology Group (ECOG) performance status - 0, 1, 2, 3
At the Investigator's discretion and with approval of the sponsor, participants meeting all of the following eligibility criteria are eligible to enter the extension phase:
1. All participants randomized into the oral azacitidine or placebo arm and are continuing in either the treatment phase or follow-up phase of the CC-486-AML-001 study;
* Participants randomized to oral azacitidine treatment arm and continuing in the treatment phase demonstrating clinical benefit as assessed by the investigator are eligible to receive oral azacitidine in the extension phase (EP);
* Participants randomized into placebo arm of the study will not receive oral azacitidine in the EP, but will be followed for survival in the EP;
* Participants currently in the follow-up phase will continue to be followed for survival in the EP;
2. Participants who have signed the informed consent for the EP of the study;
3. Participants who do not meet any of the criteria for study discontinuation
Exclusion Criteria
2. Prior bone marrow or stem cell transplantation
3. Have achieved CR/CRi following therapy with hypomethylating agents
4. Diagnosis of malignant disease within the previous 12 months
5. Proven central nervous system (CNS) leukemia
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Oncology Associates, P.C.
Phoenix, Arizona, United States
Providence St Joseph Medical Center Cancer Center
Burbank, California, United States
City Of Hope
Duarte, California, United States
University of California San Francisco Fresno Campus
Fresno, California, United States
University of Southern California Norris Cancer Center
Los Angeles, California, United States
Local Institution - 006
Los Angeles, California, United States
Local Institution - 050
Orange, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Stanford Cancer Center
Stanford, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Local Institution - 010
Southington, Connecticut, United States
George Washington University Cancer Center
Washington D.C., District of Columbia, United States
Local Institution - 046
Gainesville, Florida, United States
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
Local Institution - 044
Orlando, Florida, United States
Northwestern University Medical Center
Chicago, Illinois, United States
Loyola University Chicago
Maywood, Illinois, United States
Cancer Care and Hematology Specialists of Chicagoland, P.C. - Niles, IL
Niles, Illinois, United States
Local Institution - 013
Indianapolis, Indiana, United States
Franciscan St. Francis Health
Indianapolis, Indiana, United States
Local Institution - 003
Westwood, Kansas, United States
Local Institution - 049
Louisville, Kentucky, United States
Local Institution - 058
Louisville, Kentucky, United States
Local Institution - 047
New Orleans, Louisiana, United States
Ochsner Medical Center - Jefferson Highway
New Orleans, Louisiana, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Local Institution - 015
Worcester, Massachusetts, United States
Local Institution - 037
Rochester, Minnesota, United States
Local Institution - 023
Kansas City, Missouri, United States
Washington University School Of Medicine
St Louis, Missouri, United States
Local Institution - 057
Omaha, Nebraska, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Winthrop University Hospital
Mineola, New York, United States
Local Institution - 009
New York, New York, United States
Columbia University Irving Medical Center
New York, New York, United States
Local Institution - 002
New York, New York, United States
Local Institution - 004
Rochester, New York, United States
Local Institution - 014
Valhalla, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Local Institution - 025
Winston-Salem, North Carolina, United States
Local Institution - 016
Cleveland, Ohio, United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Kaiser Permanente Northwest Oncology Hematology
Portland, Oregon, United States
Lancaster General Hospital
Lancaster, Pennsylvania, United States
UPMC Cancer Pavillion
Pittsburgh, Pennsylvania, United States
Greenville Hospital System
Greenville, South Carolina, United States
Local Institution - 011
Nashville, Tennessee, United States
Local Institution - 007
Nashville, Tennessee, United States
Local Institution - 041
Dallas, Texas, United States
Local Institution - 034
Fort Sam Houston, Texas, United States
Local Institution - 001
Houston, Texas, United States
Cancer Care Centers of South Texas - Loop
San Antonio, Texas, United States
Local Institution - 039
San Antonio, Texas, United States
Local Institution - 035
Richmond, Virginia, United States
Swedish Cancer Inst
Seattle, Washington, United States
Yakima Valley Memorial Hospital/ North Star Lodge
Yakima, Washington, United States
Froedtert Hospital BMT Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Local Institution - 510
Wollongong, New South Wales, Australia
Local Institution - 509
South Brisbane, Queensland, Australia
Local Institution - 508
Adelaide, South Australia, Australia
Local Institution - 511
Bedford Park, South Australia, Australia
Local Institution - 504
Woodville South, South Australia, Australia
Local Institution - 503
Heidelberg, , Australia
Local Institution - 502
Hobart, , Australia
Local Institution - 507
Liverpool, , Australia
Local Institution - 500
Melbourne, , Australia
Local Institution - 505
Perth, , Australia
Local Institution - 512
Perth, , Australia
Local Institution - 506
St Leonards, , Australia
Local Institution - 501
Woolloongabba, , Australia
Local Institution - 271
Graz, , Austria
Local Institution - 270
Salzburg, , Austria
Local Institution - 274
Vienna, , Austria
Local Institution - 272
Vienna, , Austria
Local Institution - 273
Vienna, , Austria
Local Institution - 300
Bruges, , Belgium
Local Institution - 301
Charleroi, , Belgium
Local Institution - 302
Mons, , Belgium
Local Institution - 233
Curitiba, Paraná, Brazil
Local Institution - 231
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 232
Rio de Janeiro, , Brazil
Local Institution - 234
São Paulo, , Brazil
Local Institution - 230
São Paulo, , Brazil
Local Institution - 605
Edmonton, Alberta, Canada
Local Institution - 600
Winnipeg, Manitoba, Canada
Local Institution - 601
Saint John, New Brunswick, Canada
Local Institution - 603
St. John's, Newfoundland and Labrador, Canada
Local Institution - 604
Halifax, Nova Scotia, Canada
Local Institution - 607
Toronto, Ontario, Canada
Local Institution - 608
Montreal, Quebec, Canada
Local Institution - 602
Montreal, Quebec, Canada
Local Institution - 320
Brno, South Moravian, Czechia
Local Institution - 321
Prague, , Czechia
Local Institution - 322
Prague, , Czechia
Local Institution - 361
Helsinki, , Finland
Local Institution - 362
Tampere, , Finland
Local Institution - 360
Turku, , Finland
Local Institution - 456
Amiens, , France
Local Institution - 465
Argenteuil, , France
Local Institution - 457
Bobigny, , France
Local Institution - 462
Boulognes Sur Mer, , France
Local Institution - 460
Clamart, , France
Local Institution - 452
Créteil, , France
Local Institution - 458
Le Chesnay, , France
Local Institution - 453
Lille, , France
Local Institution - 461
Limoges, , France
Local Institution - 450
Lyon, , France
Local Institution - 463
Paris, , France
Local Institution - 454
Paris, , France
Local Institution - 800
Paris, , France
Local Institution - 464
Pontoise, , France
Local Institution - 455
Rouen, , France
Local Institution - 459
Saint-Cloud, , France
Local Institution - 451
Villejuif, , France
Local Institution - 400
Dresden, Saxony, Germany
Local Institution - 413
Berlin, , Germany
Local Institution - 410
Bonn, , Germany
Local Institution - 406
Düsseldorf, , Germany
Local Institution - 415
Erlangen, , Germany
Local Institution - 404
Frankfurt am Main, , Germany
Local Institution - 412
Goch, , Germany
Local Institution - 405
Hanover, , Germany
Local Institution - 408
Heilbronn, , Germany
Local Institution - 414
Jena, , Germany
Local Institution - 403
Keil, , Germany
Local Institution - 402
Mannheim, , Germany
Local Institution - 409
München, , Germany
Local Institution - 411
München, , Germany
Local Institution - 407
Oldenburg, , Germany
Local Institution - 416
Schweiler, , Germany
Local Institution - 401
Ulm, , Germany
Local Institution - 950
Dublin, , Ireland
Local Institution - 951
Galway, , Ireland
Local Institution - 381
Beersheba, , Israel
Local Institution - 380
Haifa, , Israel
Local Institution - 383
Jerusalem, , Israel
Local Institution - 382
Petah Tikva, , Israel
Local Institution - 701
Alessandria, , Italy
Local Institution - 721
Bari, , Italy
Local Institution - 720
Bologna, , Italy
Local Institution - 710
Cagliari, , Italy
Local Institution - 702
Cremona, , Italy
Local Institution - 708
Florence, , Italy
Local Institution - 712
Genova, , Italy
Local Institution - 716
Lecce, , Italy
Local Institution - 706
Milan, , Italy
Local Institution - 726
Milan, , Italy
Local Institution - 704
Monza, , Italy
Local Institution - 717
Naples, , Italy
Local Institution - 725
Naples, , Italy
Local Institution - 705
Orbassano (TO), , Italy
Local Institution - 703
Palermo, , Italy
Local Institution - 719
Palermo, , Italy
Local Institution - 724
Pesaro, , Italy
Local Institution - 700
Reggio Calabria, , Italy
Local Institution - 709
Roma, , Italy
Local Institution - 714
Roma, , Italy
Local Institution - 723
Roma, , Italy
Local Institution - 722
Rome, , Italy
Local Institution - 715
Torino, , Italy
Local Institution - 718
Torino, , Italy
Local Institution - 711
Udine, , Italy
Local Institution - 707
Varese, , Italy
Local Institution - 750
Klaipėda, , Lithuania
Local Institution - 252
Huixquilucan de Degollado, , Mexico
Local Institution - 251
México, , Mexico
Local Institution - 250
Monterrey, , Mexico
Local Institution - 824
Bydgoszcz, , Poland
Local Institution - 820
Gdansk, , Poland
Local Institution - 822
Lodz, , Poland
Local Institution - 821
Warsaw, , Poland
Local Institution - 823
Wroclaw, , Poland
Local Institution - 841
Coimbra, , Portugal
Local Institution - 840
Lisbon, , Portugal
Local Institution - 843
Lisbon, , Portugal
Local Institution - 842
Porto, , Portugal
Local Institution - 844
Porto, , Portugal
Local Institution - 971
Moscow, , Russia
Local Institution - 970
Nizhny Novgorod, , Russia
Local Institution - 972
Saint Petersburg, , Russia
Local Institution - 973
Saint Petersburg, , Russia
Local Institution - 535
Busan, , South Korea
Local Institution - 533
Daegu, , South Korea
Local Institution - 536
Seoul, , South Korea
Local Institution - 530
Seoul, , South Korea
Local Institution - 531
Seoul, , South Korea
Local Institution - 532
Seoul, , South Korea
Local Institution - 872
Palma de Mallorca, Balearic Islands, Spain
Local Institution - 867
A Coruña, , Spain
Local Institution - 869
Badalona (Barcelona), , Spain
Local Institution - 871
Barcelona, , Spain
Local Institution - 870
Barcelona, , Spain
Local Institution - 873
Cáceres, , Spain
Local Institution - 863
Córdoba, , Spain
Local Institution - 868
Madrid, , Spain
Local Institution - 866
Madrid, , Spain
Local Institution - 865
Madrid, , Spain
Local Institution - 864
Oviedo, , Spain
Local Institution - 861
Salamanca, , Spain
Local Institution - 862
Seville, , Spain
Local Institution - 860
Valencia, , Spain
Local Institution - 599
Beitou District, Taipei City, , Taiwan
Local Institution - 595
Niaosong District Kaohsiung City, , Taiwan
Local Institution - 596
Taichung, Northern Dist., , Taiwan
Local Institution - 597
Tainan, Taiana, , Taiwan
Local Institution - 598
Taipei, Zhongzheng Dist., , Taiwan
Local Institution - 653
Ankara, , Turkey (Türkiye)
Local Institution - 650
Ankara, , Turkey (Türkiye)
Local Institution - 651
Istanbul, , Turkey (Türkiye)
Local Institution - 652
Samsun, , Turkey (Türkiye)
Local Institution - 904
Nottingham, Nottinghamshire, United Kingdom
Local Institution - 907
Boston, , United Kingdom
Local Institution - 903
Brighton East Sussex, , United Kingdom
Local Institution - 902
Canterbury Kent, , United Kingdom
Local Institution - 905
London, , United Kingdom
Local Institution - 901
London, , United Kingdom
Local Institution - 908
London, , United Kingdom
Local Institution - 909
Maidstone, , United Kingdom
Local Institution - 900
Manchester, , United Kingdom
Local Institution - 906
Romford, Essex, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roboz GJ, Montesinos P, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayar H, Porkka K, Marlton P, Almeida A, Mohan S, Ravandi F, Garcia-Manero G, Skikne B, Kantarjian H. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19.
Ravandi F, Dohner H, Wei AH, Montesinos P, Pfeilstocker M, Papayannidis C, Lai Y, Wang K, See WL, de Menezes DL, Petrlik E, Prebet T, Roboz GJ. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. Br J Haematol. 2024 Mar;204(3):877-886. doi: 10.1111/bjh.19202. Epub 2023 Nov 12.
Wei AH, Roboz GJ, Dombret H, Dohner H, Schuh AC, Montesinos P, Selleslag D, Bondarenko SN, Prebet T, Lai Y, Skikne B, Beach CL, Ravandi F. Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Haematologica. 2023 Oct 1;108(10):2820-2825. doi: 10.3324/haematol.2022.282296. No abstract available.
Dohner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueno A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293.
Zhu J, Wu Q, Wang J, Niu T. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia. Expert Rev Hematol. 2022 Apr;15(4):375-382. doi: 10.1080/17474086.2022.2061456. Epub 2022 May 11.
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne B, Zhong J, Beach CL, Risueno A, Menezes DL, Ossenkoppele G, Dohner H. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022 Apr 7;139(14):2145-2155. doi: 10.1182/blood.2021013404.
Ravandi F, Roboz GJ, Wei AH, Dohner H, Pocock C, Selleslag D, Montesinos P, Sayar H, Musso M, Figuera-Alvarez A, Safah H, Tse W, Sohn SK, Hiwase D, Chevassut T, Pierdomenico F, La Torre I, Skikne B, Bailey R, Zhong J, Beach CL, Dombret H. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. J Hematol Oncol. 2021 Aug 28;14(1):133. doi: 10.1186/s13045-021-01142-x.
Wei AH, Dohner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Cakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Cermak J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
FDA Safety Alerts and Recalls
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-003457-28
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CC-486-AML-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.